Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Pathol ; 216(4): 451-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18798220

ABSTRACT

Immunotherapy by adoptive transfer of autologous tumour-infiltrating lymphocytes (TIL) shows promising clinical results for stage III (lymph nodes metastasis) melanoma patients, but some of them remain unresponsive. Here we analysed retrospectively the impact of resistance of melanoma cells to anti-proliferative cytokines on the clinical outcome of 24 TIL-treated metastatic melanoma patients. Patient relapse-free survival correlated significantly with Oncostatin M (OSM) and/or IL-6 sensitivity of melanoma cells, but not with interferon (IFN) gamma or tumour necrosis factor (TNF) alpha sensitivity. However, OSM/IL-6 sensitivity did not correlate with other known prognostic factors. Moreover, OSM and IL-6 were produced by TIL just before their injection to patients. In immunodeficient mice, OSM reduced human melanoma xenograft tumour growth, this effect being directly through inhibition of tumour cell proliferation rather than induction of apoptosis or necrosis. Thus, OSM/IL-6 resistance of melanoma cells appears to be a new escape mechanism to TIL treatment that could be added to the existing prognostic factors for early stage melanoma patients. This mechanism of action could be also relevant in other immunotherapy protocols, and could lead to better prognosis and anti-cancer treatments.


Subject(s)
Adoptive Transfer/methods , Interleukin-6/therapeutic use , Lymphocytes, Tumor-Infiltrating/transplantation , Melanoma/therapy , Oncostatin M/therapeutic use , Skin Neoplasms/therapy , Animals , Blotting, Western/methods , Cell Line, Tumor , Cell Proliferation/drug effects , Disease-Free Survival , Follow-Up Studies , Humans , Interleukin-6/metabolism , Lymphatic Metastasis , Lymphocytes, Tumor-Infiltrating/metabolism , Melanoma/drug therapy , Melanoma/pathology , Mice , Mice, Nude , Neoplasm Staging , Oncostatin M/metabolism , Receptors, Interleukin-6/metabolism , Receptors, Oncostatin M/metabolism , Retrospective Studies , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Xenograft Model Antitumor Assays
2.
Scand J Immunol ; 63(6): 401-9, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16764693

ABSTRACT

Dendritic cells (DC) are powerful antigen-presenting cells that have drawn many attentions due to the recent development of anti-cancer vaccines. Clinical grade production of monocyte-derived DC (Mo-DC) is extensively studied, and many efforts are made to develop and improve clinical standard operating procedures. Most of the parameters involved, such as the cytokines and maturation agents, have been widely assessed. However, very few are investigated about how culture medium and additional protein components affect DC yield, viability and maturation. Thus, our study aimed to compare the impact of standard culture medium on Mo-DC differentiation and maturation. Commercially available media for hematopoietic cell culture as well as different protein supplementations, that is foetal calf serum (FCS), autologous plasma (AP), human serum (HS) and human serum albumin (HSA) were tested. Culture yields, cell viability and DC maturation were investigated. Differentiation yields were similar between the conditions used. However, we evidenced significant differences in terms of cytotoxicity and DC maturation (phenotypic and functional). This underscores the importance of defining culture medium composition in clinical standard operating procedures to insure quality control, and also when preparing DC for experimental uses.


Subject(s)
Cell Differentiation/immunology , Culture Media, Conditioned , Dendritic Cells/cytology , Proteins , Cell Culture Techniques/methods , Cell Line, Tumor , Cells, Cultured , Coculture Techniques , Culture Media, Conditioned/pharmacology , Culture Media, Serum-Free/pharmacology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Humans , Phagocytosis/immunology , Serum Albumin/physiology
3.
Clin Exp Metastasis ; 19(2): 175-80, 2002.
Article in English | MEDLINE | ID: mdl-11964082

ABSTRACT

Apoptosis dysfunction in metastases has been suggested to participate in their poor response to conventional anticancer treatments. To address this question, we have analyzed the sensitivity to cell death induced by non-steroid anti-inflammatory drug, Sulindac, the most common drug used in colon cancer chemotherapy, 5-fluorouracil (5-FU) and the short chain fatty acid, butyrate (Bu) in cell lines derived from a primary colorectal tumor (ALT-I) as well as the liver (ALT-F) and the lymph-node (ALT-G) metastases. We have previously shown both in vitro by analyzing anchorage-independent cell proliferation and in vivo by subcutaneous injection into athymic nude mice that the ALT-F and ALT-G cells were more tumorigenic than the primary ALT-I cells. All these cell lines, derived from an untreated patient, were highly resistant to apoptosis induced by 5-FU and Sulindac but were sensitive to Bu-induced apoptosis. The resistance to apoptosis was, as quantified by the induction of caspase activity and the relative percentage of apoptotic cells, higher in the metastatic cell lines, than in the ALT cell line. When compared to the primary tumor, more anti-apoptotic bcl-2 and less pro-apoptotic bax were expressed in the liver and lymph node metastatic cell lines. Quite remarkably, the expression of bax was up-regulated during Bu-treatment, a feature that could explain its powerful pro-apoptotic activity.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Butyrates/pharmacology , Colonic Neoplasms/pathology , Fluorouracil/pharmacology , Liver Neoplasms/secondary , Lymphatic Metastasis/pathology , Annexin A5/metabolism , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Blotting, Western , Colonic Neoplasms/metabolism , Drug Resistance, Neoplasm , HT29 Cells/drug effects , HT29 Cells/metabolism , Humans , Liver Neoplasms/metabolism , Phenotype , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Sulindac/pharmacology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Suppressor Protein p53/metabolism , bcl-2-Associated X Protein , bcl-X Protein
4.
Cancer Immunol Immunother ; 50(8): 417-27, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11726136

ABSTRACT

Dendritic cells (DC) have been shown to be efficient antigen-presenting cells (APC) and, as such, could be considered ideal candidates for cancer immunotherapy. Immature DC (iDC) efficiently capture surrounding antigens; however, only mature DC (mDC) prime naive T lymphocytes. Clinical trials using DC-based tumor vaccines have achieved encouraging, but limited, success, possibly due to the use of immature or incompletely mature DC. Thus, it was apparent that a method capable of generating large numbers of fully functional iDC, their pulsing with desired form of tumor antigens and the subsequent complete and reproducible maturation of iDC is needed. Therefore, we compared two different methods of producing large numbers of iDC. Both protocols yielded comparable numbers of cells with an iDC phenotype with phagocytic function. We next determined which of the clinically applicable activators could induce the complete and reproducible maturation of DC, in order to define the most suitable combination for future clinical trials. Only a combination of TNFalpha + Poly (I:C), or a previously described cytokine cocktail of TNFalpha + IL-1beta + IL-6 + prostaglandin E2, induced the complete activation of the whole DC population, as assessed by the cell surface expression of CD83 and costimulatory molecules. The matured DC were functionally superior to iDC in their ability to stimulate the proliferation of allogeneic lymphocytes and autologous keyhole limpet hemocyanin (KLH)-specific T lymphocytes. Furthermore, only the combination of TNFalpha + Poly (L:C) activated DC to produce large amounts of biologically active p70 IL-12. Thus DC maturation by TNFalpha + Poly (I:C) could efficiently bias T cell response towards Th1 response. Implementation of our results into clinical protocols used for DC generation could be beneficial for future immunotherapy trials.


Subject(s)
Cell Culture Techniques/methods , Dendritic Cells/cytology , Interleukin-12/metabolism , Apoptosis , Cell Differentiation , Cell Division , Cell Survival , Cells, Cultured/cytology , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Dinoprostone/pharmacology , Flow Cytometry , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hemocyanins/immunology , Humans , Immunophenotyping , Interleukin-1/pharmacology , Interleukin-12/chemistry , Interleukin-13/pharmacology , Interleukin-6/pharmacology , Lymphocyte Culture Test, Mixed , Melanoma/pathology , Phagocytosis , Poly I-C/pharmacology , Protein Structure, Tertiary , Recombinant Proteins/pharmacology , Reproducibility of Results , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology
5.
Int J Cancer ; 81(4): 629-36, 1999 May 17.
Article in English | MEDLINE | ID: mdl-10225455

ABSTRACT

In order to elucidate the role of myofibroblasts in tumor development, we compared fibroblastic reactions and their implications in the immune response in progressive and regressive rat colorectal-tumor models. Immunohistochemical analyses revealed that T lymphocytes and monocytes/macrophages were found outside progressive tumors that were surrounded by a large sheath of myofibroblasts. In vitro experiments using fibroblast- vs. myofibroblast-containing collagen gels showed that the mechanical properties of these tumor-activated myofibroblasts prevent penetration of T lymphocytes and macrophages within tumor nodules. These results indicate that tumor-activated myofibroblasts may prevent physical contact between cancer-cells and immune cells, an essential phenomenon for effective destruction of cancer cells. Successful immunotherapy against cancer should therefore include complementary treatments against these tumor-associated fibroblasts.


Subject(s)
Adenocarcinoma/immunology , Colonic Neoplasms/immunology , Interleukin-6/physiology , Macrophages/immunology , T-Lymphocytes/immunology , 1,2-Dimethylhydrazine , Adenocarcinoma/chemically induced , Adenocarcinoma/pathology , Animals , Cell Division , Colonic Neoplasms/chemically induced , Colonic Neoplasms/pathology , Fibroblasts/immunology , Fibroblasts/pathology , Gene Transfer Techniques , Genetic Vectors , Interleukin-6/genetics , Macrophages/pathology , Monocytes/immunology , Monocytes/pathology , Neoplasm Invasiveness , Rats , Rats, Inbred Strains , Recombinant Proteins/biosynthesis , T-Lymphocytes/pathology , Transfection , Tumor Cells, Cultured
6.
Pathobiology ; 67(5-6): 306-10, 1999.
Article in English | MEDLINE | ID: mdl-10725809

ABSTRACT

Cellular therapy prospects for cancer are based on the development of T cell response, resulting in efficient tumor rejection and long-term protection. We have previously shown that treatment combining injection of interleukin-2 and tumor-derived apoptotic bodies, but not tumor cell extracts, permits to reject parental tumor in 40% of rats. We observed the implication of antigen-presenting cells (APCs) and tumor-derived apoptotic bodies in the rejection of established peritoneal carcinomatosis. We demonstrated that apoptotic bodies could be efficiently phagocytosed by monocytes, triggering them to an APC phenotype. When using these phagocytosing APCs, derived from peritoneal or blood monocytes, the remission rate reached 80% of rats. However, due to the lack of specific markers of rat monocyte-derived cells, the precise role of APCs, dendritic cells and/or macrophages responsible for this therapeutic improvement remained to be clarified. In order to elucidate this question, we developed an in vivo preventive cellular therapy based on tumor-derived apoptotic bodies, where macrophages were either depleted or activated. We report here that in a preventive antitumoral apoptotic body vaccination that allows survival for 40% of treated rats, the antitumor response was characterized by a specific long-term memory (cured rats rejected a second parental tumor cell challenge). Depletion of resident macrophages with silica or clodronate liposomes appeared to promote apoptotic body vaccination efficiency, increasing the treatment to 66% of success. In this case, FACS analysis showed that peritoneal cells present are essentially immature APCs and freshly recruited NK cells. In contrast, the onset of peritoneal inflammation by thioglycollate, inducing massive recruitment and activation of macrophages, reduced the overall survival, whatever the treatment was. Also, even though the surviving rate was better in silica-treated rats than control, no long-term protection was elicited. Our data suggest that massive inflammation, recruiting numerous activated macrophages, could inhibit tumor antigen presentation by 'professional' APCs having phagocytosed apoptotic bodies, and defavor a specific antitumoral T cell response. Although effective responses were developed against parental tumor cells with silica/apoptotic body treatment, they seemed only partial, limited to primary cytotoxic efficiency. In conclusion, even if macrophages did not appear necessary for a primary response to tumor cells, these cells seemed to be implicated in the establishment of memory and long-term antitumor response.


Subject(s)
Antigen-Presenting Cells/immunology , Apoptosis/immunology , Cancer Vaccines/therapeutic use , Colonic Neoplasms/prevention & control , Dendritic Cells/immunology , Macrophages/immunology , Vaccination , Animals , Butyric Acid/pharmacology , Colonic Neoplasms/immunology , Flow Cytometry , Interleukin-1/immunology , Macrophage Activation , Phagocytosis/immunology , Rats , Treatment Outcome , Tumor Cells, Cultured
7.
Res Immunol ; 149(7-8): 673-9, 1998.
Article in English | MEDLINE | ID: mdl-9851522

ABSTRACT

Due to their resistance to classical chemotherapies, most human colorectal cancers have a high incidence and a poor prognosis. Immunotherapy using interleukin 2 (IL2) has provided disappointing results in the treatment of these cancers. Recently, however, we have demonstrated that a treatment combining a cell-differentiating agent, sodium butyrate (NaBut) with IL2 resulted in a remission of established peritoneal colorectal carcinomatosis in rats. Separately, neither NaBut nor IL2 treatment cured these tumour-bearing rats. NaBut is known to induce cell differentiation and subsequent apoptosis in epithelial cells, while IL2 stimulates the immune cells capable of participating in tumour rejection. We postulated that the significant therapeutic effect of NaBut/IL2 treatment could be attributed to a NaBut-induced increase in the immunogenicity of the cancer cells. We report here that NaBut induced an apoptotic process in rat colon tumour cells in vivo and in vitro. We observed, in an efficient cure, colocalization of apoptotic bodies and monocytes/macrophages at the periphery of the tumour. We propose that these apoptotic bodies are phagocytosed in vivo by the macrophages. We also showed in vitro that a subpopulation of macrophages involved in the phagocytic clearance of apoptotic cells expresses cell surface molecules associated with antigen presentation and stimulates the proliferation of naive splenocytes. Our data suggest that therapies that recruit massive induction of the apoptotic process in tumour cells could favour tumour antigen presentation via their specific phagocytosis by antigen-presenting cells (APCs). We propose that the development of specific therapies that stimulate both tumour cell apoptosis and the immune system could offer new opportunities in anti-cancer treatments of poorly immunogenic cancer cells.


Subject(s)
Antigen Presentation/immunology , Apoptosis/immunology , Colorectal Neoplasms/immunology , Macrophages/immunology , Phagocytosis/immunology , Animals , Butyrates/pharmacology , Cell Division , Humans , Phagocytes/immunology , Rats , Spleen/cytology , Tumor Cells, Cultured
8.
Bull Cancer ; 83(3): 197-204, 1996 Mar.
Article in French | MEDLINE | ID: mdl-8695921

ABSTRACT

Sodium butyrate (NaB) is known to induce the process of cell differentiation, particularly for epithelial colonic cells. We previously observed that treatment with NaB in association with interleukin 2 (IL2), cures 60% of peritoneal carcinomatosis induced by injection of DHDK12/TRb cells in syngenic rats [15]. In the present work, we evidenced in vitro metabolic alterations of the DHDK12/TRb cell line treated with NaB, followed by an apoptotic process. Flow cytometric analysis evidenced that the tumour cells were arrested in the G1 and G2 phases of the cell cycle for the adherent cells to the plastic. Biological analysis of cells and debris released in the culture medium were essentially apoptotic cells. Complementary, the NaB-induced apoptotic process was confirmed by the staining of the nucleus from releasing cells by Hoechst 33258 and the DNA fragmentation revealed by DNA electrophoresis. Mitochondrial activity and glucose consumption were significantly stimulated after NaB treatment, which reveal an alteration of the metabolic activity of the treated tumour cells. As a consequence, we measured a significant increase of the active TGF beta 1 production, a cytokine previously described to participate to the epithelial cell differentiation. These in vitro data were confirmed in vivo showing a significant expression of apoptotic tumour cells in NaB- or NaB/IL2-treated tumours. Thus, the present results in the rat peritoneal carcinomatosis treatment show that combination of apoptotic process induced by NaB with immunostimulation by IL2 has powerful therapeutic properties.


Subject(s)
Apoptosis/drug effects , Butyrates/pharmacology , Colonic Neoplasms/metabolism , Animals , Butyrates/therapeutic use , Cell Cycle/drug effects , Cell Line , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , DNA, Neoplasm/drug effects , Drug Therapy, Combination , Flow Cytometry , Immunohistochemistry , In Vitro Techniques , Interleukin-2/pharmacology , Interleukin-2/therapeutic use , Nucleosomes/drug effects , Rats , Transforming Growth Factor beta/biosynthesis , Tumor Cells, Cultured
9.
J Immunol Methods ; 186(2): 267-74, 1995 Oct 26.
Article in English | MEDLINE | ID: mdl-7594626

ABSTRACT

Transforming growth factor beta (TGF-beta) is released by a variety of cells and known to be involved in many different processes including the immune response, wound healing and carcinogenesis. As most experimental investigations have been based on quantitative analysis of TGF-beta production using a bioassay, it seemed important to test the validity and limitations of this method. This paper analyses several parameters that may impair TGF-beta quantification by bioassay. Recommendations are made concerning the influence of technical parameters and the presence of other cytokines (EGF and bFGF) commonly released by cultured cells to which the Mv1Lu mink lung epithelial cell line (CCL64) is sensitive.


Subject(s)
Biological Assay/methods , Lung/drug effects , Transforming Growth Factor beta/analysis , Animals , Blood Physiological Phenomena , Carcinoma/metabolism , Cattle , Cell Line , Colonic Neoplasms/metabolism , Culture Media, Conditioned , Culture Media, Serum-Free/pharmacology , Cytokines/metabolism , Dose-Response Relationship, Drug , Epidermal Growth Factor/pharmacology , Epithelium/drug effects , Epithelium/metabolism , Fibroblast Growth Factor 2/pharmacology , Growth Inhibitors/analysis , Growth Inhibitors/pharmacology , Humans , Lung/cytology , Lung/metabolism , Mink , Preservation, Biological , Recombinant Proteins/pharmacology , Sensitivity and Specificity , Swine , Transforming Growth Factor beta/pharmacology
10.
Cancer Res ; 54(24): 6526-32, 1994 Dec 15.
Article in English | MEDLINE | ID: mdl-7987852

ABSTRACT

Many tumors are surrounded by a highly fibrous stroma composed of fibroblasts and extracellular matrix. This desmoplastic response has been suggested to both inhibit and favor tumor progression. The present study deals with the effects of tumor cells on the fibroblastic reactions they cause and relates this to progression or regression of tumors. Two rat colon carcinoma cell lines, one which develops progressive tumors when injected s.c. in syngeneic animals (PROb cell line) and the other which develops regressive tumors in similar conditions (REGb cell line), were compared by the fibroblastic reaction which they cause. Comparative histological analysis of progressive and regressive tumors developed by the two cell lines showed a significant but opposite response of fibroblastic compartment. The progressive tumor nodules were observed to grow within a loose tissue, whereas the regressive tumor cells were surrounded by a fibrous capsule. Immunohistological labelings revealed the presence of alpha-smooth muscle actin-positive myofibroblasts during the tumor expansion, while these specific cells disappeared during the tumor regression. Immunostainings of transforming growth factor beta 1 showed an increasing staining of the progressive tumor cells during tumor development but a slight expression by tumor cells and stroma during the tumor regression. This growth factor was demonstrated to facilitate initial steps of the tumor progression by addition of active transforming growth factor beta 1 at the time of s.c. injection of PROb cells in syngeneic rat models. In vitro experimental analysis with the use of neutralizing antibody showed that active transforming growth factor beta produced by the progressive cells inhibited fibroblast proliferation and facilitated their differentiation into myofibroblasts. Since the number of myofibroblasts increased with time in progressive tumors, their presence may constitute a potential growth advantage for tumor growth. In contrast, our results indicated involvement of platelet-derived growth factor-like protein(s) in fibroblast proliferation under the control of regressive cells and the presence of an important sheath of alpha-smooth muscle actin-negative fibroblasts in regressive tumors may support a role for this growth factor in vivo. Thus, the ability of tumor cells to produce or induce the production of transforming growth factor beta or platelet-derived growth factor may give rise to a specific fibroblast reaction, which in turn may determine consequent tumor evolution.


Subject(s)
Colorectal Neoplasms/pathology , Fibroblasts/pathology , Transforming Growth Factor beta/physiology , Actins/analysis , Animals , Cell Differentiation/physiology , Colorectal Neoplasms/chemistry , Culture Media, Conditioned/pharmacology , Desmin/analysis , Fibroblasts/physiology , Male , Muscle, Smooth/chemistry , Platelet-Derived Growth Factor/pharmacology , Rats , Transforming Growth Factor beta/analysis , Transforming Growth Factor beta/pharmacology , Vimentin/analysis
11.
Bull Cancer ; 80(3): 225-34, 1993 Mar.
Article in French | MEDLINE | ID: mdl-8173175

ABSTRACT

Two types of human fibroblasts have been isolated from a patient with a colon cancer with metastasis, one type was derived from a healthy part of the colon, and the other one isolated from a metastasized lymph node close to the intestine. These fibroblasts have been characterized for their expression of collagens type I, III and IV, vimentin, fibronectin, alpha-smooth muscle actin, laminin and desmin. The effects of conditioned media of human colon cancer cell lines, HT29, SW1116, LS180 and HCT8R, on the metabolism of these fibroblasts were tested. All the conditioned media stimulate both types of fibroblasts, as reflected by their incorporation of radiolabelled methionine and proline. Normal fibroblasts were highly sensitive to the conditioned media as compared to the activated fibroblasts. Additionally, the production of TGF beta 1 by the four colorectal cancer cell lines has been quantified, and significant qualitative (production of latent and/or active form) and quantitative differences were observed. The effects of the conditioned media of the four tumoral cell lines and exogenous TGF beta 1 on the proliferation of the two types of fibroblasts were compared. Our data indicated that the two types of fibroblasts respond differently to TGF beta 1 whereas they are both growth stimulated by the conditioned media, apart from the LS180 conditioned medium. We conclude that if TGF beta 1 acts in the fibroblastic reaction, additional factors are required.


Subject(s)
Colonic Neoplasms/metabolism , Fibroblasts/metabolism , Transforming Growth Factor beta/physiology , Cell Division/drug effects , Colonic Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Humans , Transforming Growth Factor beta/genetics , Tumor Cells, Cultured
12.
Calcif Tissue Int ; 46(1): 20-7, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2153039

ABSTRACT

The aims of this study were (1) to determine at the crystal level, the nonspecific biological fate of different types of calcium phosphate (Ca-P) ceramics after implantation in various sites (osseous and nonosseous) in animals and (2) to investigate the crystallographic association of newly formed apatitic crystals with the Ca-P ceramics. Noncommercial Ca-P ceramics identified by X-ray diffraction as calcium hydroxylapatite (HA), beta-tricalcium phosphate (beta-TCP), and biphasic calcium phosphates (BCP) (consisting of beta-TCP/HA = 40/60) were implanted under the skin in connective tissue, in femoral lamellar cortical bone, articular spine bone, and cortical mandibular and mastoidal bones of animals (mice, rabbits, beagle dogs) for 3 weeks to 11 months. In humans, HA or beta-TCP granules were used to fill periodontal pockets, and biopsies of the implanted materials were recovered after 2 and 12 months.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Calcium Phosphates , Ceramics , Prostheses and Implants , Animals , Crystallization , Dogs , Durapatite , Hydroxyapatites , Mice , Microscopy, Electron , Rabbits , X-Ray Diffraction
13.
Article in English | MEDLINE | ID: mdl-2765689

ABSTRACT

The purpose of the present work was to study the response of human periodontium to hydroxyapatite biomaterial particles (180-200 microns). The biomaterial was implanted in two infra-osseous periodontal defects (two patients) after clearing of the granulation tissue. At two months post-surgery, biopsies were studied using light and electron microscopy. No sign of inflammation was observed, the biomaterial aggregates were surrounded either by typical fibroblasts or larger phagocytotic cells with phagocytosis vesicles containing biomaterial crystals. These intracellular crystals were noticeably smaller than the non-phagocytized ones. Some of the phagocytized crystals showed morphological signs of intracellular dissolution. The spaces between the crystals constitutive of the aggregates were filled with organic substance containing collagen fibers.


Subject(s)
Dental Implantation , Hydroxyapatites/pharmacology , Periodontium/drug effects , Biopsy , Humans , Materials Testing , Microscopy, Electron , Particle Size , Periodontium/ultrastructure , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...